Semi-parametric modelling for costs of health care technologies
- PMID: 15568210
- DOI: 10.1002/sim.2012
Semi-parametric modelling for costs of health care technologies
Abstract
Cost data that arise in the evaluation of health care technologies usually exhibit highly skew, heavy-tailed and, possibly, multi-modal distributions. Distribution-free methods for analysing these data, such as the bootstrap, or those based on the asymptotic normality of sample means, may often lead to inefficient or misleading inferences. On the other hand, parametric models that fit the data (or a transformation of the data) equally well can produce very different answers. We consider a Bayesian approach, and model cost data with a distribution composed of a piecewise constant density up to an unknown endpoint, and a generalized Pareto distribution for the remaining tail.
2005 John Wiley & Sons, Ltd.
Similar articles
-
Parametric modelling of cost data in medical studies.Stat Med. 2004 Apr 30;23(8):1311-31. doi: 10.1002/sim.1744. Stat Med. 2004. PMID: 15083485
-
A Bayesian model averaging approach for cost-effectiveness analyses.Health Econ. 2009 Jul;18(7):807-21. doi: 10.1002/hec.1404. Health Econ. 2009. PMID: 18792078
-
Bayesian cost-effectiveness analysis from clinical trial data.Stat Med. 2001 Mar 15;20(5):733-53. doi: 10.1002/sim.861. Stat Med. 2001. PMID: 11241573
-
Estimating genealogies from unlinked marker data: a Bayesian approach.Theor Popul Biol. 2007 Nov;72(3):305-22. doi: 10.1016/j.tpb.2007.06.004. Epub 2007 Jun 22. Theor Popul Biol. 2007. PMID: 17681576 Review.
-
An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Allergy. 2008 Jun;63(6):670-84. doi: 10.1111/j.1398-9995.2008.01723.x. Allergy. 2008. PMID: 18445184 Review.
Cited by
-
Review of statistical methods for analysing healthcare resources and costs.Health Econ. 2011 Aug;20(8):897-916. doi: 10.1002/hec.1653. Epub 2010 Aug 27. Health Econ. 2011. PMID: 20799344 Free PMC article. Review.
-
Confounding and missing data in cost-effectiveness analysis: comparing different methods.Health Econ Rev. 2013 Mar 28;3(1):8. doi: 10.1186/2191-1991-3-8. Health Econ Rev. 2013. PMID: 23537421 Free PMC article.
-
Costing and cost analysis in randomized controlled trials: caveat emptor.Pharmacoeconomics. 2009;27(3):179-88. doi: 10.2165/00019053-200927030-00001. Pharmacoeconomics. 2009. PMID: 19354338 Free PMC article.